ABSTRACT
Circulating microRNAs (miRNAs) are emerging as promising biomarkers for several disorders and related pain. In equine practice, acute laminitis is a common disease characterised by intense pain that severely compromises horse welfare. Recently, the Horse Grimace Scale (HGS), a facial expression-based pain coding system, was shown to be a valid welfare indicator to identify pain linked to acute laminitis. The present study aimed to: determine whether miRNAs can be used as biomarkers for acute pain in horses (Equus caballus) affected by laminitis; integrate miRNAs to their target genes and to categorise target genes for biological processes; gather additional evidence on concurrent validity of HGS by investigating how it correlates to miRNAs. Nine horses presenting acute laminitis with no prior treatment were recruited. As control group, nine healthy horses were further included in the experimental design. Samples were collected from horses with laminitis at admission before any treatment ('pre-treatment') and 7 days after routine laminitis treatment ('post-treatment'). The expression levels of nine circulating miRNAs, namely hsa-miR-532-3p, hsa-miR-219-5p, mmu-miR-134-5p, mmu-miR-124a-3p, hsa-miR-200b-3p, hsa-miR-146a-5p, hsa-miR-23b-3p, hsa-miR-145-5p and hsa-miR-181a-5p, were detected and assessed as potential biomarkers of pain by quantitative PCR using TaqMan® probes. The area under the receiver operating curve (AUC) was then used to evaluate the diagnostic performance of miRNAs. Molecular data were integrated with HGS scores assessed by one trained treatment and time point blind veterinarian. The comparative analysis demonstrated that the levels of miR-23b-3p (P=0.029), miR-145-5p (P=0.015) and miR-200b-3p (P=0.023) were significantly higher in pre-treatment and the AUCs were 0.854, 0.859 and 0.841, respectively. MiR-200b-3p decreased after routine laminitis treatment (P=0.043). Combining two miRNAs in a panel, namely miR-145-5p and miR-200b-3p, increased efficiency in distinguishing animals with acute pain from controls. In addition, deregulated miRNAs were positively correlated to HGS scores. Computational target prediction and functional enrichment identified common biological pathways between different miRNAs. In particular, the glutamatergic pathway was affected by all three miRNAs, suggesting a crucial role in the pathogenesis of pain. In conclusion, the dynamic expression of circulating miR-23b-3p, miR-145-5p and miR-200b-3p was detected in horses with acute laminitis and miRNAs can be considered potentially promising pain biomarkers. Further studies are needed in order to assess their relevancy in other painful conditions severely compromising horse welfare. An important implication would be the possibility to use them for the concurrent validation of non-invasive indicators of pain in horses.
Subject(s)
Acute Pain/veterinary , Animal Welfare , Circulating MicroRNA/blood , Foot Diseases/veterinary , Horse Diseases/diagnosis , Acute Pain/blood , Acute Pain/diagnosis , Acute Pain/pathology , Animals , Area Under Curve , Biomarkers/blood , Circulating MicroRNA/genetics , Female , Foot Diseases/blood , Foot Diseases/diagnosis , Foot Diseases/pathology , Hoof and Claw/pathology , Horse Diseases/blood , Horse Diseases/pathology , Horses , Inflammation/veterinary , Male , Real-Time Polymerase Chain Reaction/veterinaryABSTRACT
A truthful snapshot of horse welfare conditions is a prerequisite for predicting the impact of any actions intended to improve the quality of life of horses. This can be achieved when welfare information, gathered by different assessors in diverse geographical areas, is valid, comparable and collected in a harmonized way. This paper aims to present the first outcomes of the Animal Welfare Indicators (AWIN) approach: the results of on-farm assessment and a reliable and harmonized data collection system. A total of 355 sport and leisure horses, stabled in 40 facilities in Italy and in Germany, were evaluated by three trained assessors using the AWIN welfare assessment protocol for horses. The AWINHorse app was used to collect, store and send data to a common server. Identified welfare issues were obesity, unsatisfactory box dimensions, long periods of confinement and lack of social interaction. The digitalized data collection was feasible in an on-farm environment, and our results suggest that this approach could prove useful in identifying the most relevant welfare issues of horses in Europe or worldwide.
Subject(s)
Animal Husbandry/standards , Animal Welfare , Horses/physiology , Animals , Data Collection , Germany , Italy , Quality of Life , SportsABSTRACT
The aim of the present study was to obtain information on the possible mechanisms underlying cribbing behaviour in horses. To investigate the horse's responsiveness to an external stimulus, a device for telemetric measurement of thermal threshold, using the forelimb withdrawal reflex, was developed and validated. Measurements of thermal threshold took place in cribbing horses (n = 11) before and during cribbing periods. Heart rate was monitored continuously in the same horses. Blood samples were collected before and during cribbing periods as well and in age- and sex-matched control horses (n = 11). beta-endorphin and cortisol were determined in plasma using radioimmunoassay techniques, serotonin was analysed by high performance liquid chromatography. Compared with basal values, thermal threshold was significantly (P = 0.003) lower during cribbing periods. The mean difference was 4.9 degrees C. Heart rate decreased significantly (P = 0.026) and showed a mean reduction of 2.4 beats/min during cribbing. Given the fact that arousal usually is associated with an increase in nociceptive threshold and in heart rate, the decrease in both during cribbing provide evidence that cribbing may reduce stress. Cribbers showed 3 times higher basal beta-endorphin levels than controls (mean 49.5 vs. 16.2 pmol/l, P = 0.006) and there was a trend for lower basal serotonin levels (mean 201.5 vs. 414.3 nmol/l, P = 0.07). These data indicate differences in cribber's endogenous opioid and serotonergic systems.